Reviewing Ionis Pharmaceuticals (IONS) and Compugen (CGEN)

Ionis Pharmaceuticals (NASDAQ: IONS) and Compugen (NASDAQ:CGEN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Ionis Pharmaceuticals and Compugen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 2 5 6 0 2.31
Compugen 0 0 1 0 3.00

Ionis Pharmaceuticals currently has a consensus target price of $51.33, suggesting a potential downside of 1.62%. Compugen has a consensus target price of $14.00, suggesting a potential upside of 218.18%. Given Compugen’s stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than Ionis Pharmaceuticals.

Valuation and Earnings

This table compares Ionis Pharmaceuticals and Compugen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals $507.67 million 12.89 -$5.96 million $0.80 65.23
Compugen $710,000.00 317.85 -$37.06 million ($0.72) -6.11

Ionis Pharmaceuticals has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Ionis Pharmaceuticals has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Compugen has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Insider & Institutional Ownership

91.0% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.4% of Compugen shares are owned by institutional investors. 2.1% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Ionis Pharmaceuticals and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals -1.18% -1.94% -0.50%
Compugen N/A -87.08% -72.10%


Ionis Pharmaceuticals beats Compugen on 9 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply